相关实验视频
Updated: Jun 16, 2025

04:16
Electrocardiogram Recordings in Anesthetized Mice using Lead II
Published on: June 20, 2020
12.7K
在心力衰竭患者中,药物诱导的QT间隔延长,具有保存的喷射分数
Chien-Yu Huang1, Brian R Overholser1,2, Kevin M Sowinski1,2
1Department of Pharmacy Practice, College of Pharmacy, Purdue University, West Lafayette and Indianapolis, Indiana, United States of America.
PloS one
|August 19, 2024
概括
患有心力衰竭和保留射出分数 (HFpEF) 的患者在服用多菲提利德或索塔醇时,QT间隔延长的风险增加. 这一发现突出了对需要这些药物的HFpEF患者的关键安全考虑.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 降低射出率心力衰竭 (HFrEF) 是药物诱导的QT间隔延长的已知危险因素.
- 心力衰竭与保存的喷射分数 (HFpEF) 和QT延长风险之间的关联尚未得到充分证实.
- 多菲提利德和索塔醇经常被处方给心房动的HFpEF患者,尽管它们具有强大的QT延长作用.
研究的目的:
- 为了调查HFpEF是否与QT间隔延长的风险增加有关,在接受多菲提利德或索塔醇治疗的患者中.
- 为了比较HFpEF患者的QT延长风险与HFrEF患者和没有心力衰竭的患者的风险.
主要方法:
- 使用印第安纳州患者护理网络 (2010-2021) 电子健康记录进行的回顾性队列研究.
- 已确定患有HFpEF,HFrEF和没有HF的患者正在接受多菲提利德或索塔洛.
- 定义QT延长为校正QT (QTc) > 500毫秒;使用一般化估计方程 (GEE) 进行分析,并对多个共变量进行调整.
主要成果:
- QTc延长发生在53.2%的HFpEF患者,71.7%的HFrEF患者和30.0%没有HF的患者中.
- 调整后的分析显示,HFpEF患者 (OR = 1.98) 和HFrEF患者 (OR = 5.23) 的QTc延长几率与没有HF患者相比显著更高.
- 无论是HFpEF还是HFrEF,都显著增加了使用多菲提利德或索塔醇的QT延长的几率.
结论:
- 与多菲提利德和索塔醇相关的QT间隔延长的风险在患有HFpEF的患者中显著增加,类似于HFrEF.
- 这些发现强调了在服用这些药物的HFpEF患者中仔细监测QT延长的重要性.
- 在临床实践中,在治疗心房动或其他心律失常时,应考虑HFpEF中QTc延长的风险增加.
相关概念视频
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
940
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
940
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Heart Failure Drugs: Inotropic Agents
547
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
547
Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
Heart Failure Drugs: β-Blockers
324
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
324
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
800
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
800

